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Background: T regulatory cell (Treg) plays a critical role in respiratory allergy and allergen-specific immunotherapy
(SIT), and γδ T cells might participate in mediating Treg quantity and/or function in some immunological diseases.
To further characterize whether γδ T cells could influence Treg in allergic rhinitis (AR) and SIT, we investigated the
expression pattern of Treg’s Foxp3 gene and γδ T cell receptor (TCR) Vγ subfamily genes in peripheral blood
mononuclear cells (PBMCs) of AR patients before and after SIT.
Methods: Eighteen AR patients undergoing effective SIT with house dust mite extract for one year were
recruited. Visual Analogue Scale (VAS) was applied to evaluate the severity. Immunofluorescence quantification
analysis was performed to determine the serum specific IgE (sIgE) content. Real-time PCR was used to detect the
expression levels of Foxp3 and TCR Vγ subfamilies. Ten healthy volunteers were recruited as the controls.
Results: Nasal uni-VAS score after SIT was significantly lower than that before SIT, while serum sIgE content was
similar before and after SIT. Expression levels of Foxp3 and TCR Vγ subfamilies in AR patients before treatment
were significantly lower than those in healthy subjects. Expression levels of VγI and II were similar before and
after SIT, while expression levels of Foxp3 and VγIII after SIT were significantly higher than those before. Before
SIT, the significant positive correlation was observed between expression levels of Foxp3 and VγI, II, III,
while negative correlation was observed between Foxp3, VγIII and VAS. After SIT, the significant positive
correlation between expression levels of Foxp3 and VγIII and negative correlation between Foxp3, VγIII and VAS
were observed.
Conclusions: Treg and Vγ subfamily T cells were in a dynamic equilibrium in AR patients before and after
effective immunotherapy for one year. The early improvement of symptoms following immunotherapy might be
independent of the serum sIgE content in AR patients, but associated with the reconstitution of T cell immunity.
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Allergic Rhinitis (AR) is part of the systemic allergic
disease, which involves the formation of specific IgE
antibodies against innocuous environmental substances.
Allergen-specific immunotherapy (SIT) is currently the
only therapeutic choice to alter the natural course of AR
and has gradually become the first-line treatment, yet its
functional mechanism has not been fully elucidated. It* Correspondence: yang.qt@163.com
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stated.has been reported that T regulatory cell (Treg) quantity
and/or function were reduced in allergic diseases [1],
and SIT could make the quantity rebound and/or the
function recover [2]. Previous studies from others [3]
and us [4] have found that CD4-CD8- γδ T cells predom-
inantly expressed in mucous membrane participate in
respiratory allergy. Various functional subsets of γδ T
cells could promote or suppress allergic inflammation
under different conditions, and clinical effectiveness of
SIT was possibly related to the induction of inflamma-
tion suppression by the subsets of γδ T cells [5]. It was
confirmed in a recent study that γδ T cells could limitLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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plenty of IL-17, thus promoting autoimmune inflamma-
tion [6]. However, the role of γδ T cells in allergic in-
flammation has not yet been reported. The aim of this
study was to investigate the expression pattern of differ-
ent γδ T cell subfamilies (subsets) as well as their poten-
tial correlation with Treg in untreated AR and after early
SIT by testing the expression levels of Foxp3 and TCR




The subjects of the study were 18 patients with moder-
ate to severe persistent AR sensitized to house dust
mites (7 males and 11 females; median age: 25 years,
range: 6 ~ 38 years). All patients were diagnosed based
on ARIA guideline (Allergic Rhinitis and its Impact on
Asthma; 2008 update [7]), and received SIT with stan-
dardized house dust mite extract (standardized immuno-
therapy protocol of the University of Copenhagen,
Denmark) for 1 year at the Third Affiliated Hospital of
Sun Yat-Sen University. The clinical characteristics of
the patients were listed on Table 1. The therapy was ef-
fective based on the effective criteria [8]. Peripheral
blood samples were obtained from the patients at the
beginning of their immunotherapy and after one year’s
treatment. One month before SIT, all subjects were
withheld from oral corticosteroids, antihistamines orTable 1 Clinical characteristics of AR patients




1 Female 10 8.36 2.87
2 Male 22 7.94 2.37
3 Male 25 7.92 0.46
4 Female 25 7.89 1.74
5 Female 36 8.09 3.82
6 Male 12 7.03 3.54
7 Female 31 7.35 1.47
8 Male 31 7.83 1.72
9 Female 38 6.96 2.13
10 Female 6 7.51 1.68
11 Female 12 7.85 2.26
12 Female 21 7.97 3.68
13 Male 27 8.27 2.54
14 Female 17 8.01 0.37
15 Female 35 7.99 0.96
16 Male 25 7.63 2.44
17 Male 21 7.42 3.06
18 Female 37 7.72 3.18immunotherapy. Ten healthy individuals with no symp-
tom of any allergic diseases and negative serum sIgE
served as the control group (4 males and 6 females; me-
dian age: 27.5 years, range: 16 ~ 40 years). Serums were
separated by low-speed centrifugation. The PBMCs were
isolated using Ficoll-Hypaque gradient centrifugation
method. RNA extraction and cDNA synthesis was per-
formed according to the manufacturer’s instructions [9].
All samples were obtained with written informed con-
sent from the participants, and all of the procedures
were conducted according to the guidelines of the Med-
ical Ethics Committee of Health Bureau of China before
study initiation.
Visual analogue scale
The severity of the nasal symptoms of 18 AR patients
before and after immunotherapy was assessed according
to Visual Analogue Scale (VAS) [10]. The global discom-
fort caused by AR during the previous week of the test
was rated on a 0-10 scale, 0 being no symptom, and 10
being the maximal severity of the symptom.
Serum specific IgE detection
The contents of serum specific IgE (sIgE) against the
house-dust-mite allergen before and after SIT were de-
tected using the automatic system of immunofluorescence
quantitative analysis (UniCAP 100E; Pharmacia, Sweden).
Real-time polymerase chain reaction for Foxp3 and TCR
VγI ~ III subfamily genes
Real-time polymerase chain reaction (PCR) was used to
determine Foxp3 and TCR VγI ~ III gene expression
levels in the PBMCs from samples. Beta 2-microglobulin
(β2M) gene was used as an endogenous reference. The
sequences of primers were listed in Table 2. PCR was
performed as previously described [11,12]. In brief, 20 μl
PCR reaction mixture containing approximately 1 μL of
cDNA, 0.6 mmol/L of each primer, and 10 μl of 2.5×
Real Master Mix (Tiangen Biotech (Beijing) Co. Ltd.,
Beijing, China) was prepared. Amplification was carried
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lows: 15 minutes’ initial denaturation at 95°C, 44 cycles
consisted of 30 seconds at 95°C; 40 seconds at 60°C; and
2 seconds at 82°C. The melting curve was obtained from
55 to 95°C (0.5°C/s). The 2(–ΔCT) method was used to
calculate the relative amount of the genes of interest.
Statistical analysis
The Student’s t test or Mann-Whitney U test was per-
formed to compare the means of gene expression levels
in different groups. Data were presented as mean ± SD.
Pearson correlation or Spearman’s rank correlation ana-
lysis was used to estimate the correlations. Statistical
analysis was performed using SPSS version 16.0 statistic
software package. Differences were considered statisti-
cally significant at P < 0.05.
Results
VAS scores and serum sIgE contents before and after SIT
in AR patients
Mean nasal uni-VAS score of 18 AR patients at the be-
ginning of treatment was 7.61 ± 0.34, and after immuno-
therapy for one year significantly decreased to 2.02 ±
0.98 (t = 20.772, P < 0.001), indicating an alleviation of
the nasal hypersensitivity. The mean content of serum
sIgE was similar before and after SIT (22.17 ± 8.64 kU/L
and 19.72 ± 7.18 kU/L, respectively; Z = 1.051, P = 0.278).
Expression pattern of Foxp3 and TCR Vγ subfamilies in AR
patients and healthy subjects
The expression pattern of TCR Vγ subfamily genes was
VγII > VγI > VγIII in PBMCs from healthy subjects. In
contrast, it was VγI > VγII > VγIII in AR patients both be-
fore and after SIT. Significantly lower expression levels of
Foxp3 (0.20 ± 0.25), VγI (1.02 ± 0.81), VγII (0.99 ± 0.86)Figure 1 The relative expression levels of Foxp3 and TCR Vγ subfamiand VγIII (0.39 ± 0.26) were observed in untreated AR
patients compared with healthy subjects (Foxp3: 0.37 ±
0.28, Z = -2.253, P = 0.024; VγI: 1.59 ± 0.89, Z = -2.158,
P = 0.031; VγII: 2.59 ± 1.28, Z = -3.069, P = 0.002; VγIII:
0.71 ± 0.19, t = 3.345, P = 0.003). After SIT, the expres-
sion levels of VγI and VγII in AR patients were 1.21 ±
0.48 and 0.96 ± 0.49, respectively, not significantly dif-
ferent from those before SIT (VγI: t = -0.977, P = 0.342;
VγII: Z = -0.501, P = 0.616, respectively). However, the ex-
pression levels of Foxp3 and VγIII were obviously in-
creased after SIT (Foxp3: 0.81 ± 0.54, t = -0.977, P = 0.342;
VγIII: 0.90 ± 0.69, Z = -0.501, P = 0.616) (Figure 1).
Correlation analysis of Foxp3 and TCR Vγ subfamily genes
There was no significant correlation between the ex-
pression levels of Foxp3 and TCR VγI ~ III genes in
healthy subjects (P = 0.533, r = 0.224; P = 0.082, r = -0.576;
P = 0.987, r = 0.006, respectively). Significant positive
correlation of the expression levels of Foxp3 and TCR
VγI ~ III genes was found before SIT (P = 0.001, r = 0.717;
P = 0.017, r = 0.553; P < 0.001, r = 0.825, respectively).
After SIT, the expression level of Foxp3 had no signifi-
cant correlation with those of TCR VγI or VγII genes
(P = 0.932, r = 0.022; P = 0.367, r = 0.226), but was positively
related to the expression level of VγIII gene (P = 0.014,
r = 0.567) (Figure 2).
Correlation analysis of VAS score, Foxp3 and TCR Vγ
subfamily genes
In AR patients before SIT, significant negative correl-
ation was observed between the VAS score and the ex-
pression level of Foxp3 (P = 0.002, r = -0.684), and
between the VAS score and the expression level of TCR
VγIII (P = 0.044, r = -0.480). After SIT for one year, with
the expression level of Foxp3 gene increasing and TCRlies before and after SIT.
Figure 2 Correlations between Foxp3 and TCR Vγ gene expression levels before and after SIT. (A) Foxp3 vs. TCR VγI in the before SIT
group; (B) Foxp3 vs. TCR VγII in the before SIT group; (C) Foxp3 vs. TCR VγIII in the before SIT group; (D) Foxp3 vs. TCR VγIII in the after SIT group.
Significant positive correlations were indicated.
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between the levels of these two genes and the VAS score
(P < 0.001, r = -0.737; P = 0.017, r = -0.556, respectively)
(Figure 3).
Correlation analysis of Foxp3, TCR Vγ subfamily genes,
VAS score and sIgE levels
No significant correlation was shown between the expres-
sion levels of Foxp3, TCR Vγ subfamily genes, VAS score
and the contents of serum sIgE in AR patients before
or after SIT for one year. (Before SIT: P = 0.763, r = -0.076;
P = 0.711, r = -0.094; P = 0.720, r = -0.091; P = 0.750,
r = 0.081; P = 0.943, r = 0.018, respectively. After SIT:
P= 0.403, r= -0.210; P= 0.380, r= -0.220; P= 0.556, r= 0.149;
P = 0.475, r = -0.180; P = 0.657, r = 0.112, respectively).
Discussion
SIT could restore the body’s immune tolerance and also
rectify the body’s immune imbalance, making it the only
etiological therapy for allergic diseases at present [13].
Though SIT has been practiced for more than a hundred
years, and its safety and effectiveness have been con-
firmed with the implement of standardized allergenvaccines, it has not been well clarified regarding its role
during the course of therapy. AR is a kind of type I aller-
gic disease primarily mediated by IgE. Serum sIgE level
is the important clinical criteria to diagnose AR, and is
supposed to decline in patients under effective SIT.
However, recent studies have shown that serum sIgE
level increased but not decreased in the early stage of
SIT, and a long therapeutic process was required to ob-
serve the reduction in sIgE [14,15]. Similar results were
found in our study, which showed that the serum sIgE
level after one-year-long SIT was similar to that before
SIT. Moreover, there was no significant correlation be-
tween sIgE level and VAS score. These data suggest that
serum sIgE level has no linear correlation with the im-
provement of clinical symptoms in the early stage of
SIT, thus it cannot serve as an objective criteria to evalu-
ate the effectiveness of SIT. We speculate that patients
with AR cannot be isolated from house dust mite anti-
gen, which may result in the continued existence of al-
lergic humoral immunity and continuous generation of
sIgE during early SIT. Consequently, the improvement
of nasal symptoms in the early stage of SIT is likely to
benefit from the cellular immunity mediated by T cells.
Figure 3 Correlations between VAS score, Foxp3 and TCR Vγ gene expression levels before and after SIT. (A) VAS vs. Foxp3 in the before
SIT group; (B) VAS vs. TCR VγIII in the before SIT group; (C) VAS vs. Foxp3 in the after SIT group; (D) VAS vs. TCR VγIII in the after SIT group.
Significant negative correlations were indicated.
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scholar Sakaguchi in 1995 and was demonstrated to act
as a vital immune modulator to maintain body’s immune
homeostasis [16]. Studies have shown that CD4+CD25+
Treg can inhibit excessive type I hypersensitivity mainly
through its related cytokines IL-10 and TGF-β. Forkhead
box p3 (Foxp3), a specific transcription factor of Treg,
plays an essential role in Treg’s development and func-
tion. The mRNA expression level of Foxp3 can directly
reflect Treg’s quantity and functional status in vivo [17].
It has been verified that Foxp3+Treg quantity and/or
function decrease in the peripheral blood of patients
with respiratory allergy, and recover after immunother-
apy [2,18]. This study showed that Foxp3 mRNA expres-
sion level in PBMCs was significantly lower in the AR
patients group than in the control group, suggesting a
reduction of Treg quantity thus a hindered immunosup-
pressive function in AR. In contrast, in AR patients after
SIT for one year, Foxp3 mRNA expression level signifi-
cantly increased, suggesting the rectification of Treg
quantity and/or function. In addition, with Foxp3 mRNA
expression level ascending and VAS score descending, a
significant negative correlation between them wasmaintained before and after SIT. These results suggest
that Treg may play a pivotal role in the inhibition of pa-
tients’ symptoms caused by allergic inflammation.
The γδ T cells mainly distribute in the skin, small in-
testine, lung, and reproductive organs, and engage in the
mucosal immune processes. Respiratory mucosal im-
munological barrier imbalance contributes largely to the
occurrence of AR and asthma, and the role of γδ T cells
play in these allergic diseases has received more attention
[19]. It was reported that γδ T cells presented dual-
directional regulatory function under different conditions
via secreting diverse cytokines, which regulated what
functional subsets γδ Tcells were divided into [20]. For in-
stance, γδ T cells showed a Th1 effect by generating IL-2
and INF-γ when bacterial infection occurred inside cells;
but showed a Th2 effect by stimulating B cells with IL-4
and IL-5 with extracellular parasite infection. Additionally,
human γδ T cells can be divided into several subsets based
on different combinations of Vγ and Vδ chains at the vari-
able regions of the T cell receptors. Among them, VγI
subsets consist of Vγ2, 3, 4, 5 and 8, VγII subsets
contain Vγ9, and VγIII subsets include Vγ10 [21]. In
animals, Vγ1+γδ T subsets could aggravate airway
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subsets. In contrast, Vγ4+γδ T subsets restrained AHR
and had a protective effect on airway mucosa, belong-
ing to anti-inflammation subsets [3,6]. Though there
are differences in the distribution of γδ T cell subsets
between humans and animals and between different or-
gans, it is affirmed that γδ T cells contain both pro- and
anti-inflammation subsets. The aim of this study was to
determine the functional subsets that each VγI ~ III sub-
families belong to by testing the gene expression levels of
VγI ~ III in PBMCs from AR patients before and after
SIT. Our results showed that VγI ~ III expression levels in
PBMCs from AR patients before SIT were all significantly
lower than those in healthy controls, and VγIII expression
level was negatively correlated to VAS score. After SIT for
one year, changes in VγI and VγII expression levels in
PBMCs had no statistical significance compared with
those before SIT, while VγIII expression level significantly
increased and was negatively correlated with VAS score.
These results suggest that Vγ subfamilies, especially VγIII,
were closely related to the occurrence of AR. In addition,
VγIII subfamily might play an anti-inflammation role in
the early stage of SIT, thereby alleviating clinical symp-
toms of AR patients.
In some immunological diseases, γδ T cells were found
to influence the differentiation and function of Treg via
secreting plenty of INF-γ, IL-17 or other cytokines for
local inflammation [6,22]. Nevertheless, it has not yet
been reported which subfamilies of γδ T cells are related
to Treg in AR and SIT. This study showed that the ex-
pression levels of both VγI and VγII subfamily genes in
PBMCs were positively related to that of Foxp3 gene,
and the expression level of VγIII subfamily gene was
positively related to that of Foxp3 gene both before and
after SIT. These results strongly suggest that there exists
a mutual regulatory effect and some dynamic equilib-
rium between Treg and TCR Vγ subfamilies, especially
VγIII, in AR and the early stage of SIT. Future studies
with larger sample size will further confirm the dynamic
equilibrium between Treg and γδ T cells in peripheral
blood as well as in nasal mucosa of AR patients before
and after SIT.
Conclusions
We characterized the expression pattern of Foxp3 gene
and three TCR Vγ subfamily genes as well as the potential
correlation between them in the PBMCs of AR patients
before and after one-year-long effective SIT. The results
showed that Treg and Vγ subfamily T cells were in a dy-
namic equilibrium in AR patients before and after effect-
ive immunotherapy for one year. The early improvement
of symptoms following immunotherapy might be inde-
pendent of the serum sIgE content in AR patients, but as-
sociated with the reconstitution of T cell immunity.Competing interests
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